Long-term clinical outcomes of laparoscopy-assisted distal gastrectomy versus open distal gastrectomy for early gastric cancer
A comprehensive systematic review and meta-analysis of randomized control trials

Wei Lu (MD, PhD)\textsuperscript{a,b,*}, Jian Gao (MD)\textsuperscript{c,d}, Jingyun Yang (PhD)\textsuperscript{e,f}, Yijian Zhang (PhD)\textsuperscript{a,b}, Wenjie Lv (MD)\textsuperscript{a}, Jiasheng Mu (MD, PhD)\textsuperscript{a}, Ping Dong (MD)\textsuperscript{a}, Yingbin Liu (MD, PhD)\textsuperscript{a,b,*}

Abstract
The objective of this study was to compare long-term surgical outcomes and complications of laparoscopy-assisted distal gastrectomy (LADG) with open distal gastrectomy (ODG) for the treatment of early gastric cancer (EGC) based on a review of available randomized controlled trials (RCTs) evaluated using the Cochrane methodology.

RCTs comparing LADG and ODG were identified by a systematic literature search in PubMed, Cochrane Library, MEDLINE, EMBASE, Scopus, and the China Knowledge Resource Integrated Database, for papers published from January 1, 2003 to July 30, 2015. Meta-analyses were performed to compare the long-term clinical outcomes.

Our systematic literature search identified 8 eligible RCTs including 732 patients (374 LADGs and 358 ODGs), with low overall risk of bias. Long-term mortality and relapse rate were comparable for both techniques. The long-term complication rate was 8.47% in LADG groups and 13.62% in the ODG group, indicating that LADG was associated with lower risk for long-term complications (RR = 0.63; 95%CI = 0.39–1.00; \( P = 0.03 \)).

In the treatment of EGC, LADG lowered the rate of long- and short-term complications and promoted earlier recovery, with comparable oncological outcomes to ODG.

Abbreviations:
AGC = advanced gastric cancer, CI = confidence interval, CONSORT = CONsolidated Standards of Reporting Trials, EGC = early gastric cancer, FVC = forced vital capacity, GRADE = Grading of Recommendations Assessment, Development, and Evaluation, LADG = laparoscopy-assisted distal gastrectomy, ODG = open distal gastrectomy, QOL = quality of life, RCT = randomized controlled trial, RD = relative difference, RR = risk ratio, SD = standard deviation, SMD = standardized mean difference.

Keywords: clinical outcomes, early gastric cancer, laparoscopy-assisted distal gastrectomy, meta-analysis, open distal gastrectomy
1. Introduction

With the popularization and rapid advance in endoscopy surveillance, the proportion of early gastric cancer (EGC) had been elevated during the past decade. Different from advanced gastric cancer (AGC), EGC had an excellent prognosis, and the 5-year survival rate exceeds 90%. Therefore, postoperative complication and recovery become a major concern of the surgical outcomes to EGC patients. Laparoscopic surgery results in small incisions, less scarring, and faster recovery and therefore has been widely used for decades for the management of benign diseases. With recent advances in technology and surgical technique, laparoscopic surgery has been increasingly used for the treatment of EGC. However, the clinical outcomes of this procedure have not been substantially evaluated.

Laparoscopy-assisted distal gastrectomy (LADG), introduced by Kitano et al in 1995, is one of the most consistently used laparoscopic techniques for surgical resection of gastric carcinomas. With the recent rapid advancement in technique, application of laparoscopy to treat EGC had gained wide acceptance. More than 30 retrospective studies and several randomized control trials (RCTs) have been conducted to evaluate the feasibility of LADG in the clinical management of EGC. Previous meta-analyses comparing the short-term outcomes of LADG with open distal gastrectomy (ODG) provide limited evidence to guide practice due to some methodological concerns. Findings from individual RCTs are inconsistent and inconclusive, partly due to the small sample size of each individual study.

Therefore, the aim of our study was to compare oncological and surgical outcomes and complications of LADG with ODG for the treatment of EGC based on a systematic review of available RCTs using the best practices for systematic review and meta-analysis to generate high quality evidence to inform practice. We strictly adopted the guidelines for preferred reporting items for systematic reviews and meta-analyses (PRISMA), evaluated the quality of available evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Applying the principles of the CONSORT and GRADE Working Group guidelines, we also provide a summary of current limitations of available evidence to shed light on the design of future RCTs.

2. Methods

2.1. Eligibility criteria

We applied the following criteria to determine study eligibility: patients were diagnosed with EGC; patients underwent LADG in the treatment group, and ODG in the control group; outcomes of interests included long- and short-term complication; and the studies were RCTs. Short-term complications were defined as the complications that occurred within 30 days postoperatively, regardless of whether they were related to the operation or not. Long-term complications were defined as the complications related to the operation that occurred from 30 days postoperation to the end of the follow-up. Studies were excluded if robot-guided surgery was used, if a pylorus-preserving gastrectomy was performed, if surgery was performed on an emergency basis, or if measured outcomes included data for cases of malignant stromal tumors, benign disease, or were based on a high proportion of patients with AGC. Studies in which only pooled data were reported, or from which necessary data could not be extracted, were also excluded. When multiple studies by the same research group were identified, we used data merged from different reports with the same trial number.

2.2. Literature search strategies

A structured literature search was conducted in Pubmed, Cochrane Library, MEDLINE, EMBASE, the Scopus, and the China Knowledge Resource Integrated Database, for papers published from January 1, 2003 to July 31, 2015 to identify eligible RCTs. The following terms were used in the search ([(laparoscop OR (minimal invasive)) AND gastrectomy AND ([early gastric OR (early stomach)]) AND [cancer OR carcinoma OR adenocarcinoma OR malignant*)]). The search was slightly adjusted according to the requirement of different databases. A cursory review of titles and abstracts were performed (WL and JG), followed by a detailed review of potentially relevant publications. Disagreement on inclusion/exclusion of RCTs was resolved through consensus. The search was limited to papers published in English or Chinese.

2.3. Data extraction

Data were extracted independently by 2 researchers (WL and YZ) using a prepared data extraction form. Continuous variables were expressed as the mean and standard deviation (SD). To pool continuous data in which only the median and range were available, estimates of the mean and SD were calculated using the methods of Hozo et al. If the mean and SD were not reported directly, these data were extracted from published figures using Engauge Digitizer version 4.1 to calculate the means and SDs. Disagreement was resolved by consultation with a senior author (YL).

2.4. Assessment of bias and quality of evidence

Risk of bias was assessed independently by 2 reviewers (WL and JG) according to the Cochrane methodology, which includes 6 domains: selection bias, performance bias, detection bias, attrition bias, reporting bias, and other potential sources of bias. When there was insufficient information to allocate a high or low score, an "unclear" risk score was allocated. Disagreements in score allocations were resolved through group discussion. Publication bias was assessed using funnel plots and Egger regression, with P ≤ 0.1 indicative of reporting biases.

The quality of evidence of each study was assessed (WL and JG) according to the guidelines of the GRADE Working Group, using the GRADE profiler (version 3.6.1, http://ims.cochrane.org/revman/grade pro) and GRADE Handbook to determine the quality of evidence and strength of recommendation.

2.5. Data synthesis

Risk ratio (RR) and the associated 95% confidence interval (CI) were used to compare postoperative complications between LADG and ODG. Alternatively, when there was no event in either groups during the follow-up, we used relative difference (RD), defined as the difference in the incidence rate of the LADG group from that in the ODG group. Mortality was evaluated using RD. RRs were pooled using a random-effects model.
Standardized mean differences (SMDs) were pooled by using an inverse variance model. Statistical heterogeneity among studies was assessed by using the Q statistic and $I^2$.[22] Meta-analyses were performed using Review Manager Version 5.3.[23] All additional analyses were performed by using Stata/MP 12.1 (Stata Corp, College Station, TX). A $P$-value $< 0.05$ was set as the threshold of statistical significance. As a systematic review and meta-analysis, ethical approval of this study is not needed.

2.6. Sensitivity, subgroup analysis, and meta-regression

For meta-analysis with $I^2 > 70\%$, if sufficient trials were available, sensitivity analyses were conducted by excluding or subgrouping studies to reduce the potential confounding effects of age, sex, body mass index, concurrent illness, surgical type, year of publication, country of the trial, and tumor location, size, histology, and tumor, node, metastasis (TNM) stage. The log of the estimate of the study effect was set as the dependent variable in a general linear model, and $I^2$ and $P$-value were recalculated. Differences in the slopes of the linear regression models for the original and subgrouped data were used to predict contributions of these potential confounding factors on the measured outcomes.

3. Results

3.1. Study selection and characteristics

Our initial literature search identified 664 possible publications; 408 studies were excluded after the initial screening of titles and abstracts. We retrieved the full text of the 256 studies and further excluded 246 studies after full-text review. Of the 10 remaining studies, 2 RCTs reported short- and long-term outcomes separately in 2 articles. Both articles were retained in the corresponding meta-analysis. Finally, 8 RCTs reported in 10 articles were included in our meta-analysis. The flow chart for the selection of eligible studies is presented in online Fig. 1.[24–33]

As a result, our meta-analysis included data of 732 patients (374 LADG and 358 ODG). All 8 RCTs were conducted in Asia between 1998 and 2008, with their data published between 2002 and 2015. The sample size ranged from 20 to 342 patients. Overall, in 97.1% of the patients, tumors were classified as TNM stage I and were located in the body and antrum of the stomach. The distribution of the stages and locations of the tumors for the remain patients are as follows: 2.5% (18/732) with stage II tumors, 12 allocated to the LADG group and 6 to the ODG group; and 0.4% (3/732) with stage III tumors, 1 allocated to the LADG group and 6 to the ODG group. Six trials recorded the number of lymph node harvested. Patients in 3 trials consented to D2 lymphadenectomy and in another 3 trials, to D1 or D1$^+$ resection. In the remaining 2 trials, patients consented to elective dissection. Patients and tumor characteristics of the included studies are presented in Table 1.

3.2. Assessment of quality of randomized controlled trials, risk of bias, and quality of evidence

Overall, the included RCTs had low risk of bias (Fig. 2). Two of the 8 studies did not report random sequence generation and were considered as having unclear risk of bias. Regarding allocation concealment, we found no significant between-group differences in the distribution of TNM tumor stages ($P = 0.315$). Due to the inherent difficulty in performing a blinded trial of LADG and ODG, there is a risk of bias in some reported outcomes. The main characteristics of the included trials, including risk study quality, are summarized in online Supplementary Table 1, http://links.lww.com/MD/B92.

The funnel plot was symmetrical (Fig. 3), indicating the absence of reporting bias between trials included in our meta-analyses ($P = 0.119$, Egger test). The GRADE evaluation of level
of evidence for each outcome, including reasoning, is summarized in Table 2. Briefly, we evaluated a total of 20 outcomes. Of the 9 critical outcomes, 7 were considered to be of strong recommendation grade, including mortality rate, relapse rate, complication rate, number of resected lymph nodes in D2 resection, reoperation rate, and blood loss. Of the 11 important outcomes, 2 were considered to be of strong recommendation grade, including operation time and hospital stay. The remaining outcomes were considered to be of weak recommendation grade.

3.3. Primary short-term clinical outcome

Overall, short-term complications were reported in 58/374 patients in the LADG group (15.5%) and in 101/358 in the ODG group (28.2%), with a lower RR of complications in the LADG group compared with ODG (RR = 0.57; 95% CI, 0.44–0.76; P < 0.0001). We found low heterogeneity among the trials (χ² = 3.73; I² = 0%; P = 0.81; Fig. 4).

Comparison of individual complications between LADG and ODG is summarized in Table 3. Short-term mortality was reported in only 1 trial, which found that 2 patients died of chronic hepatitis B virus infection or liver cirrhosis within 31 days in the LADG group.\[30\]

The number of lymph nodes harvested was reported in 6 trials involving 185 patients (Fig. 5). Our meta-analysis found no difference in the number of harvested lymph nodes (SMD = −0.32; 95% CI: −0.65 to 0.01; P = 0.06), with significant heterogeneity (χ² = 4.02; I² = 53%; P = 0.06). Suspecting that the difference might be due to the heterogeneity between the studies, we performed subgroup analysis by strength of evidence for each individual study included in the meta-analyses; and (B) summary of risk of bias across all of the included studies. +, low risk of bias; −, high risk of bias; and ?, unclear risk of bias.

3.4. Secondary short-term clinical outcomes

We found that LADG was associated with less intraoperative blood loss (SMD = −0.94; 95% CI: −1.38 to −0.49; P < 0.0001) and ODG with shorter operative time (SMD = −2.66; 95% CI: 1.91–3.40; P < 0.0001). We also found significant differences in time to 1st postoperative flatus (SMD = −0.94; 95% CI: −1.58 to −0.29; P = 0.005), postoperative analgesic consumption (SMD = −0.79; 95% CI: −1.55 to −0.22; P = 0.04), and pain visual analog scale score at day 7 (SMD = −1.66; 95% CI: −3.23 to −0.10; P = 0.04), but not earlier. We found no significant differences in time to 1st postoperative oral intake (SMD = −0.41; 95% CI: −1.14 to −0.33; P = 0.28). LADG was also associated with shorter duration of postoperative fever (SMD = −1.03; 95% CI: −1.79 to −0.28; P = 0.007; 131 patients) and lower increase in WBC (day 3, SMD = −0.23, 95% CI: −0.46 to −0.01; P = 0.04; day 7, SMD = −0.35, 95% CI: −0.60 to −0.09; P = 0.007). However, we found no significant difference in blood albumin, C-reactive protein, interleukin 6 level, forced expiratory volume in 1 second, and forced vital capacity (see online Supplementary Table 2, http://links.lww.com/MD/B92).

3.5. Long-term clinical outcomes

We found no significant differences in rate of mortality (RD = 0.01, 95% CI: −0.01–0.02; P = 0.82), with no heterogeneity between trials (χ² = 3.68; I² = 0%; P = 0.47). Similarly, relapse rate was comparable for both groups (RD = −0.01, 95% CI:
Table 2

Rating the quality of evidences by GRADE.

| Outcomes                          | No of participants | RR/RD (95% CI) | Absolute | Quality | Importance | Recommendation grade |
|-----------------------------------|--------------------|----------------|----------|---------|------------|----------------------|
| Overall mortality rate            | 8                  | 5/374 (1.3%)   | 5/358 (1.4%) | RD 0.01 (0.01 to 0.02) | 1 Fewer per 1000 | Critical Strong |
| Disease related mortality rate    | 8                  | 2/374 (2.5%)   | 1/358 (2.5%) | RD 0.39 (0.02 to 0.02) | 1 Fewer per 1000 | Critical Strong |
| Relapse rate                      | 4                  | 1/151 (0.7%)   | 1/151 (0.7%) | RD 0.00 (0.01 to 0.01) | 1 Fewer per 1000 | Critical Strong |
| Overall long-term complications   | 8                  | 24/281 (8.5%)  | 38/265 (14.3%) | RR 0.61 (0.38 to 0.98) | 60 Fewer per 1000 | Critical Strong |
| Lymph node (D2 resection)         | 3                  | 120 (15.5%)    | 119 (28.2%) | RD 0.39 (0.04 to 0.01) | 6 Fewer per 1000 | Critical Strong |
| Lymph node (less than D2 resection)| 3                 | 65 (8.5%)      | 66 (14.3%)   | RD 0.36 (0.04 to 0.01) | 1 Fewer per 1000 | Critical Strong |
| Reoperation rate                  | 6                  | 3/268 (1.1%)   | 4/253 (1.6%) | RR 0.75 (0.18 to 3.08) | 4 Fewer per 1000 | Critical Strong |
| Blood loss                        | 8                  | 374 (1.7%)     | 330 (1.6%)  | RD 0.34 (0.3 to 0.4)   | 1 Fewer per 1000 | Critical Strong |
| Hospital stay                     | 4                  | 151 (10.1%)    | 151 (10.1%) | RD 0.34 (0.3 to 0.4)   | 1 Fewer per 1000 | Critical Strong |
| Operation time                    | 7                  | 195 (10.1%)    | 195 (10.1%) | RD 0.34 (0.3 to 0.4)   | 1 Fewer per 1000 | Critical Strong |
| Ritus                             | 6                  | 185 (10.1%)    | 185 (10.1%) | RD 0.34 (0.3 to 0.4)   | 1 Fewer per 1000 | Critical Strong |
| VAS pain score (day 7)            | 4                  | 147 (10.1%)    | 148 (10.1%) | RD 0.34 (0.3 to 0.4)   | 1 Fewer per 1000 | Critical Strong |
| Analgesic usage                   | 4                  | 83 (10.1%)     | 83 (10.1%)  | RD 0.34 (0.3 to 0.4)   | 1 Fewer per 1000 | Critical Strong |
| WBC (day 7)                       | 5                  | 157 (10.1%)    | 158 (10.1%) | RD 0.34 (0.3 to 0.4)   | 1 Fewer per 1000 | Critical Strong |
| Albumin (day 7)                   | 3                  | 137 (10.1%)    | 137 (10.1%) | RD 0.34 (0.3 to 0.4)   | 1 Fewer per 1000 | Critical Strong |
| CRP (day 7)                       | 4                  | 147 (10.1%)    | 148 (10.1%) | RD 0.34 (0.3 to 0.4)   | 1 Fewer per 1000 | Critical Strong |
| FEV1                              | 2                  | 96 (10.1%)     | 96 (10.1%)  | RD 0.34 (0.3 to 0.4)   | 1 Fewer per 1000 | Critical Strong |
| Fever                             | 3                  | 65 (10.1%)     | 66 (10.1%)  | RD 0.34 (0.3 to 0.4)   | 1 Fewer per 1000 | Critical Strong |
| Wound length                      | 4                  | 140 (10.1%)    | 139 (10.1%) | RD 0.34 (0.3 to 0.4)   | 1 Fewer per 1000 | Critical Strong |

CI = confidence interval, CRP = C-reactive protein, FEV1 = forced expiratory volume in 1 second, F = first, GRADE = Grading of Recommendations Assessment, Development, and Evaluation, LADG = laparoscopy-assisted distal gastrectomy, ODG = open distal gastrectomy, No = number, RR = risk ratio, SMD = standardized mean difference, VAS = visual score, WBC = white blood cell.
Reoperations due to abdominal complications were not included in the calculation of the number of complications. 

Meta-analysis of rate of short-term complications after LADG in comparison to ODG for the treatment of early gastric cancer. CI = confidence interval, LADG = laparoscopy-assisted distal gastrectomy, ODG = open distal gastrectomy, OR = odds ratio.

Figure 4. Meta-analysis of rate of short-term complications after LADG in comparison to ODG for the treatment of early gastric cancer. CI = confidence interval, LADG = laparoscopy-assisted distal gastrectomy, ODG = open distal gastrectomy, OR = odds ratio.

4. Discussion

In this study, we conducted a systematic review of RCTs to compare oncological and surgical outcomes and complications of LADG and ODG for the treatment of ECG. We found no significant between-group differences in oncological outcomes and in lymph node harvesting with D1 or D1+ resections. We found significantly lower long- and short-term complications and shorter postoperative hospital stay in the LADG group. LADG also improved outcomes by reducing blood loss and wound length, and accelerated postoperative recovery, with no evidence of influencing systemic inflammatory reaction and respiratory function. Our meta-analysis provided evidence for the beneficial effect of laparoscopic surgery in treating EGC.

Several meta-analyses have been conducted to compare LADG with ODG for the treatment of EGC. The 1st one, conducted in 2006, found that LADG was superior to ODG in short-term outcomes.[6,10] Findings from most recent meta-analyses also favor LADG in the evaluation of short-term clinical outcomes.[4,6–13,35,36] Meta-analysis of long-term clinical

outcome is scarce, and most of these studies did not assess the quality of evidence. Further, existing meta-analyses included mixed RCTs and non-RCTs publications (online Supplementary Table 3a,3b, http://links.lww.com/MD/B92). By adopting the best practices for systematic review and meta-analysis of RCTs, our study provided some key updates with high fidelity on the superiority of LADG over ODG in optimizing long-term survival and complications.

Although laparoscopic surgery elongated operation time, which may increase the surgical stress of the patients, we found no significant difference in C-reactive protein and interleukin 6 level between the 2 groups. Previous research indicated that laparoscopic surgery resulted in smaller wound, which can promote recovery.[37] In day 1 and day 3 after surgery, we found no significant difference in pain visual analog scale score (P = 0.11 and 0.09, respectively). However, patients in the LADG group had significantly less pain when intravenous analgesic intervention was withdrawn on day 7 (P = 0.04). As a result, patients might experience less mental stress from smaller wound and less pain. With the development of modern laparoscopic surgery instruments, we can anticipate that laparoscopic surgery might exhibit more advantages due to a better field of vision and a more detailed observation by visual magnification. However, it has to be acknowledged that LADG is demanding to the surgeons with respect to skills and experiences.

We also highlight the difficulty in lymph nodes clearance with LADG in D2 lymphadenectomy. Previous studies noticed that LADG might be inferior in lymph node clearance, which may limit the application of LADG.[6,10] A previous meta-analysis reported that there was no significant difference in lymph node clearance between LADG and ODG, but the results were based on a mixture of retrospective studies and RCTs.[18] Another meta-analysis found that laparoscopic surgery was inferior in lymph node clearance, but this analysis suffered the same limitation of including only retrospective studies.[37] We found no difference in lymphadenectomy of less than D2 resection between LADG and ODG. However, there was significantly lower efficiency in lymph node clearance in the LADG group when D2 lymphadenectomy was applied. Although this did not appear to influence the oncological outcomes of patients with EGC, the difference between laparoscopic and open harvesting of lymph nodes could play a pivotal role in the surgical treatment of AGC.[40] In such cases, ODG might be a more suitable treatment

Table 3

Meta-analysis of subtypes of LADG complications in comparison with ODG.

| Complication type/no. of studies | Case number | Incidence rate | Difference | Heterogeneity |
|----------------------------------|-------------|----------------|------------|--------------|
|                                 | LADG      | ODG         | LADG      | ODG         | Z  | RR | 95% CI | P-value |
| Respiratory system/7             | 8/292     | 17/276      | 2.14%     | 4.75%       | 1.92 | 0.49 | 0.23–1.01 | 0.05 |
| Digestive system/7               | 3/292     | 4/276       | 0.80%     | 1.12%       | 0.41 | 0.75 | 0.19–2.97 | 0.68 |
| Abdominal/8                      | 9/292     | 18/276      | 3.08%     | 6.52%       | 1.78 | 0.52 | 0.25–1.07 | 0.08 |
| Post operation bleeding/7        | 3/268     | 5/253       | 0.80%     | 1.40%       | 0.75 | 0.60 | 0.16–2.29 | 0.46 |
| Wound complication/7             | 2/292     | 8/276       | 0.53%     | 2.23%       | 1.80 | 0.28 | 0.07–1.12 | 0.07 |
| Other/7                          | 7/292     | 6/276       | 1.87%     | 1.68%       | 0.11 | 1.06 | 0.36–3.10 | 0.91 |
| Respiration/6*                   | 3/268     | 4/253       | 0.80%     | 1.12%       | 0.44 | 0.73 | 0.18–2.93 | 0.66 |
| Overall short-term complications/8| 38/374   | 101/358     | 15.51%    | 28.21%      | 4.14 | 0.56 | 0.42–0.74 | <0.0001 |
| Overall long-term complications/4| 25/295   | 38/279      | 8.47%     | 13.62%      | 1.94 | 0.63 | 0.39–1.00 | 0.03 |

Significant values are in boldface type. Respiratory system complications include atelectasis, pneumonia, and pleural effusion. Digestive system complications include delayed gastric emptying, constipation, hiccups, diarrhea, and dumping. Abdominal complications include anastomotic leakage, chyle leakage, ileus, anastomotic stenosis, intraabdominal abscess, and fluid collection. Wound complications include wound bleeding, wound infection, and wound dehiscence. Other complications include urinary tract infection, renal complication, liver function abnormality, and herpes zoster. CI = confidence interval, LADG = laparoscopy-assisted distal gastrectomy, ODG = open distal gastrectomy, OR = odds ratio.

* Resections due to abdominal complications were not included in the calculation of the number of complications.
Future studies are warranted to further evaluate the role of LADG in lymph node harvesting. The lower need for analgesic medication has been claimed to be an advantage of LADG. However, we found that the evidence supporting this claim to be of low quality due to the wide variation in type and administration of analgesic drug. These heterogeneities prevented meaningful pooling of data across RCTs for meta-analysis of the need for analgesic medication. Moreover, we found no significant difference in postoperative pain until day 7 after surgery, when patients in the LADG group reported significantly lower levels of pain.

Our study has several limitations. Although the included studies were all RCTs and strictly selected for surgical methods and study population, there was still a high level of heterogeneity, as illustrated above. Despite our efforts to conduct a literature search as systematic and comprehensive as possible, the sample size is still limited, compared to the previous meta-analysis not limited to the inclusion of only RCTs. This prevented us from performing some subgroup analysis. For example, although overall survival and disease-free survival are pivotal outcomes, we were unable to perform meta-analysis on these factors because the very low incidence of mortality made it impossible to discriminate between the surgical groups. Similarly, we could not analyze postoperative QOL and patients' satisfaction because the evidence supporting a beneficial effect of LADG on postoperative pain is deemed to be of low quality due to the high level of between-trial heterogeneity. More homogeneous studies are needed to further evaluate the effect of LADG on postoperative pain.

Figure 5. Meta-analysis of the number of lymph nodes harvested with LADG in comparison with ODG in patients with early gastric cancer. (A) D1 and D2 lymphadenectomy, (B) D2 lymphadenectomy, and (C) D1 lymphadenectomy. CI = confidence interval, LADG = laparoscopy-assisted distal gastrectomy, ODG = open distal gastrectomy, SD = standard deviation.
few of the included studies monitored these features. Moreover, all RCTs included in our meta-analyses were conducted in 2 East Asian countries (Korea and Japan), and it is not clear whether the findings can be generalized to other countries or other ethnic groups.

5. Conclusions
In summary, we conducted a systematic and comprehensive literature review and performed meta-analyses to compare LADG with ODG for the treatment of EGC. We found that LADG is beneficial regarding long-term and/or short-term
complications and hospital stay. However, it was associated with fewer harvested lymph node during D2 lymphadenectomy. Further larger and more homogeneous RCTs that take into account the effect of age, ethnicity, body mass index, and comorbidity are needed to validate our findings. Future meta-analysis taking advantage of a larger sample size from more available RCTs will also be informative to compare the clinical outcomes between LADG and ODG in the treatment of EGC.

Acknowledgments

The authors thank China National High Technology Research and Development Program (863 Program) (No. 2012AA022606); National Natural Science Foundation of China (No. 91440203, 81172026, 81272402, 81370186, and 81172029); China Postdoctoral Science Foundation (No. 2014M561487) and Interdisciplinary Program of Shanghai Jiao Tong University (No. 14JCRY05); and NIH/NIA R01AG036042 and the Illinois Department of Public Health for the support.

References

[1] Moon HS. Improving the endoscopic detection rate in patients with early gastric cancer. Clin Endosc 2015;48:291-6.
[2] Wang Z, Ma L, Zhang XM, et al. Long-term outcomes after D2 gastrectomy for early gastric cancer: survival analysis of a single-center experience in China. Asian Pac J Cancer Prev 2014;15:7219-22.
[3] Kitano S, Shimoda K, Miyahara M, et al. Laparoscopic approaches in the management of patients with early gastric carcinomas. Surg Laparosc Endosc 1995;5:559-62.
[4] Zeng YK, Yang ZL, Peng JS, et al. Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: evidence from randomized and nonrandomized clinical trials. Ann Surg 2012;256:39-52.
[5] Hosono S, Arimoto Y, Ohtani H, et al. Meta-analysis of short-term outcomes after laparoscopy-assisted distal gastrectomy. World J Gastroenterol 2006;12:7676-83.
[6] Yakoub D, Athanasiou T, Tekkis P, et al. Laparoscopic assisted distal gastrectomy for early gastric cancer: is it an alternative to the open approach? Surg Endosc 2009;18:322-33.
[7] Peng JS, Song H, Yang ZL, et al. Meta-analysis of laparoscopy-assisted distal gastrectomy and conventional open distal gastrectomy for early gastric cancer. Chin J Cancer 2010;29:349-54.
[8] Liang Y, Li G, Chen P, et al. Laparoscopic versus open gastrectomy for early distal gastric cancer: a meta-analysis. ANZ J Surg 2011;81:673-80.
[9] Wang Y, Wang S, Huang ZQ, et al. Meta-analysis of laparoscopy assisted distal gastrectomy and conventional open distal gastrectomy for EGC. Surgeon 2014;12:53-8.
[10] Chen XZ, Hu JK, Yang K, et al. Short-term evaluation of laparoscopy-assisted distal gastrectomy for early gastric cancer: meta-analysis of randomized controlled trials. Surg Laparosc Endosc Percutan Tech 2009;19:277-84.
[11] Ohtani H, Tamamori Y, Noguchi K, et al. A meta-analysis of randomized controlled trials that compared laparoscopic-assisted and open distal gastrectomy for early gastric cancer. J Gastrointest Surg 2010;14:958-64.
[12] Farlan AD, Penrick V, Bombardier C, et al. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976) 2009;34:1929-41.
[13] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
[14] Hopp L. Risk of bias reporting in Cochrane systematic reviews. Int J Nurs Pract 2013;21:683-4.
[15] Phi L, Ajay R, Ramchandani MH, et al. Expanding the grading of recommendations assessment, development, and evaluation (Ex- GRADE) for evidence-based clinical recommendations: validation study. Open Dent J 2012;6:31-40.
[16] Djulbegovic B, Kumar A, Kaufman RM, et al. Quality of evidence is a key determinant for making a strong GRADE guidelines recommendation. J Clin Epidemiol 2015;68:727-32.
[17] Murphy JF. Consort 2010 statement on randomised controlled trials. Ir Med J 2010;103:132.
[18] Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
[19] Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
[20] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
[21] Brozek J, Akl EA, Compalari E, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy 2011;66:588-95.
[22] Biggerstaff BJ, Jackson D. The exact distribution of Cochran’s Q-statistic. Stat Med 1989;8:1251-60.
[23] Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2014.
[24] Kitano S, Shiraiishi N, Fuji K, et al. A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. Surgery 2002;131:406-11.
[25] Fuji K, Sonoda K, Izumi K, et al. T lymphocyte subsets and TH1/TH2 balance after laparoscopy-assisted distal gastrectomy. Surg Endosc 2003;17:1140-4.
[26] Hayashi H, Ochiai T, Shimada H, et al. Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. Surg Endosc 2005;19:1172-6.
[27] Lee JH, Han HS, Lee JH. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results. Surg Endosc 2005;19:168-73.
[28] Kim YW, Baik YH, Yun YH, et al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg 2008;248:721-7.
[29] Kim YW, Yoon HM, Yun YH, et al. Long-term outcomes of laparoscopy-assisted distal gastrectomy for early gastric cancer: result of a randomized controlled trial (COACT 0301). Surg Endosc 2013;27:4267-76.
[30] Kim HH, Hyung WJ, Cho GS, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interrim report—a phase III multicenter, prospective, randomized Trial (KCLASS Trial). Ann Surg 2010;251:417-20.
[31] Takiguchi S, Fujiiwara Y, Yamasaki M, et al. Laparoscopic-assisted distal gastrectomy versus open distal gastrectomy. A prospective randomized single-blind study. World J Surg 2013;37:2379-86.
[32] Sakuramoto S, Yamashita K, Kikuchi S, et al. Laparoscopy versus open distal gastrectomy by expert surgeons for early gastric cancer in Japanese patients: short-term clinical outcomes of a randomized clinical trial. Surg Endosc 2013;27:1695-705.
[33] Yamashita K, Sakuramoto S, Kikuchi S, et al. Laparoscopic versus open distal gastrectomy for early gastric cancer in Japan: long-term clinical outcomes of a randomized clinical trial. Surg Today 2015.
[34] Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma -- 2nd English Edition. Gastric Cancer 1998;1:10-24.
[35] Deng Y, Zhang Y, Gao TK. Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: a meta-analysis based on seven randomized controlled trials. Asian Pac J Cancer Prev 2013;14:6225-30.
[36] Murphy JF. CASP: Critical Appraisal Skills Programme. J Clin Epidemiol 2004;57:115-25.
[37] Manz W, Sauer R, Siewert JR, et al. Long-term results of a prospective randomized clinical trial. Ann Surg 2005;241:703-11.
[38] Marano L, Polom K, Patriti A, et al. Surgical management of gastric cancer. Rev Esp Enferm Dig 2011;103:133-41.
[39] Marano L, Polom K, Patriti A, et al. Surgical management of advanced gastric cancer: an evolving issue. Eur J Surg Oncol 2016;42:18-27.